Abstract
Cystic fibrosis (CF) lung disease is characterized by persistent inflammation. Antiinflammatory drugs, such as corticosteroids and ibuprofen, have proved to slow the decline of pulmonary function although their use is limited because of frequent adverse events. We hypothesized that colchicine could be an alternative treatment because of its antiinflammatory properties and upregulatory effect on cystic fibrosis transmembrane regulator (CFTR) closely related proteins. We herein present results obtained in an open study of eight CF children treated with colchicine for at least 6 months. Clinical status was better in all patients and respiratory function tests significantly improved in five. Median duration of antibiotherapy decreased significantly. These preliminary results support our hypothesis of a beneficial effect of colchicine in CF patients and stress the need for a controlled therapeutic trial.
Full Text
The Full Text of this article is available as a PDF (109.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Altschuler E. L. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet. 1998 Apr 25;351(9111):1286–1286. doi: 10.1016/S0140-6736(05)79350-8. [DOI] [PubMed] [Google Scholar]
- Auerbach H. S., Williams M., Kirkpatrick J. A., Colten H. R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688. doi: 10.1016/s0140-6736(85)92929-0. [DOI] [PubMed] [Google Scholar]
- Dallaverde E., Fan P. T., Chang Y. H. Mechanism of action of colchicine. V. Neutrophil adherence and phagocytosis in patients with acute gout treated with colchicine. J Pharmacol Exp Ther. 1982 Oct;223(1):197–202. [PubMed] [Google Scholar]
- Douglas W. W., Ryu J. H., Swensen S. J., Offord K. P., Schroeder D. R., Caron G. M., DeRemee R. A. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med. 1998 Jul;158(1):220–225. doi: 10.1164/ajrccm.158.1.9709089. [DOI] [PubMed] [Google Scholar]
- Eliseenkova A. V., Kakpakova E. S., Abdrjashitov R. I., Stavrovskaya A. A. Colchicine-resistance and enhancement of P-glycoprotein activity after co-cultivation of drug-sensitive cells with multidrug resistant variants. Cell Biol Int. 1995 Feb;19(2):113–119. doi: 10.1006/cbir.1995.1051. [DOI] [PubMed] [Google Scholar]
- Entzian P., Schlaak M., Seitzer U., Bufe A., Acil Y., Zabel P. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung. 1997;175(1):41–51. doi: 10.1007/pl00007555. [DOI] [PubMed] [Google Scholar]
- Higgins C. F. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113. doi: 10.1146/annurev.cb.08.110192.000435. [DOI] [PubMed] [Google Scholar]
- Kelly S. J., Uri A. J., Freeland H. S., Woods E. J., Schulman E. S., Peters S. P., Fish J. E. Effects of colchicine on IgE-mediated early and late airway reactions. Chest. 1995 Apr;107(4):985–991. doi: 10.1378/chest.107.4.985. [DOI] [PubMed] [Google Scholar]
- Khan T. Z., Wagener J. S., Bost T., Martinez J., Accurso F. J., Riches D. W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995 Apr;151(4):1075–1082. doi: 10.1164/ajrccm/151.4.1075. [DOI] [PubMed] [Google Scholar]
- Koch C., Høiby N. Pathogenesis of cystic fibrosis. Lancet. 1993 Apr 24;341(8852):1065–1069. doi: 10.1016/0140-6736(93)92422-p. [DOI] [PubMed] [Google Scholar]
- Konstan M. W., Byard P. J., Hoppel C. L., Davis P. B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854. doi: 10.1056/NEJM199503303321303. [DOI] [PubMed] [Google Scholar]
- Lallemand J. Y., Stoven V., Annereau J. P., Boucher J., Blanquet S., Barthe J., Lenoir G. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet. 1997 Sep 6;350(9079):711–712. doi: 10.1016/s0140-6736(05)63510-6. [DOI] [PubMed] [Google Scholar]
- Levy M., Spino M., Read S. E. Colchicine: a state-of-the-art review. Pharmacotherapy. 1991;11(3):196–211. [PubMed] [Google Scholar]
- Linsdell P., Hanrahan J. W. Adenosine triphosphate-dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. J Gen Physiol. 1998 Apr;111(4):601–614. doi: 10.1085/jgp.111.4.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Linsdell P., Hanrahan J. W. Glutathione permeability of CFTR. Am J Physiol. 1998 Jul;275(1 Pt 1):C323–C326. doi: 10.1152/ajpcell.1998.275.1.C323. [DOI] [PubMed] [Google Scholar]
- Stern R. C. The diagnosis of cystic fibrosis. N Engl J Med. 1997 Feb 13;336(7):487–491. doi: 10.1056/NEJM199702133360707. [DOI] [PubMed] [Google Scholar]
- Tommasini R., Evers R., Vogt E., Mornet C., Zaman G. J., Schinkel A. H., Borst P., Martinoia E. The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6743–6748. doi: 10.1073/pnas.93.13.6743. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ueda K., Pastan I., Gottesman M. M. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem. 1987 Dec 25;262(36):17432–17436. [PubMed] [Google Scholar]
- Vollrath V., Wielandt A. M., Acuña C., Duarte I., Andrade L., Chianale J. Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. J Hepatol. 1994 Nov;21(5):754–763. doi: 10.1016/s0168-8278(94)80235-1. [DOI] [PubMed] [Google Scholar]
- Wei L. Y., Stutts M. J., Hoffman M. M., Roepe P. D. Overexpression of the cystic fibrosis transmembrane conductance regulator in NIH 3T3 cells lowers membrane potential and intracellular pH and confers a multidrug resistance phenotype. Biophys J. 1995 Sep;69(3):883–895. doi: 10.1016/S0006-3495(95)79962-3. [DOI] [PMC free article] [PubMed] [Google Scholar]